157 related articles for article (PubMed ID: 29161237)
1. BILATERAL VISUAL FIELD DEFECTS IN A PATIENT TREATED WITH THE MEK AND BRAF INHIBITORS TRAMETINIB AND DABRAFENIB FOR MELANOMA OF UNKNOWN ORIGIN.
Siedlecki J; Mackert M; Wolf A; Berking C; Priglinger SG; Eibl-Lindner K
Retin Cases Brief Rep; 2019 Summer; 13(3):215-219. PubMed ID: 29161237
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
4. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
5. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS
Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592
[TBL] [Abstract][Full Text] [Related]
6. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma.
Lee le M; Feun L; Tan Y
Am J Case Rep; 2014 Oct; 15():441-3. PubMed ID: 25305754
[TBL] [Abstract][Full Text] [Related]
7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
8. Ocular toxicity due to Trametinib and Dabrafenib.
Sarny S; Neumayer M; Kofler J; El-Shabrawi Y
BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062
[TBL] [Abstract][Full Text] [Related]
9. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
10. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
11. [Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors].
Rohmer E; Scrivener JN; Schissler C; Cribier B; Lenormand C
Ann Dermatol Venereol; 2019 Nov; 146(11):725-729. PubMed ID: 31627930
[TBL] [Abstract][Full Text] [Related]
12. [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
Lüdeke I; Terheyden P; Grisanti S; Lüke M
Ophthalmologe; 2016 Oct; 113(10):861-863. PubMed ID: 26873702
[TBL] [Abstract][Full Text] [Related]
13. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
14. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
16. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.
Flaherty DC; Hoffner BW; Lau BJ; Hamid O; Faries MB
J Surg Oncol; 2015 Dec; 112(8):844-5. PubMed ID: 26503563
[TBL] [Abstract][Full Text] [Related]
17. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
[TBL] [Abstract][Full Text] [Related]
18. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
[TBL] [Abstract][Full Text] [Related]
19. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
[TBL] [Abstract][Full Text] [Related]
20. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
[No Abstract] [Full Text] [Related]
[Next] [New Search]